View More View Less
  • 1 Szabolcs-Szatmár-Bereg megyei Jósa András Oktatókórház, 4400 Nyíregyháza, Lukács Ödön utca 4.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Absztrakt:

Bevezetés: A szerzők a Szabolcs-Szatmár-Bereg megyei leukémia/lymphoma regiszterben az elmúlt 35 év alatt (1983. január 1. és 2017. december 31. között) 4942 újonnan felismert, malignus hematológiai betegségben szenvedő, megyéjükben élő felnőtt beteg adatait rögzítették. A 4942 beteg között 640 akut myeloid leukémiás, 274 krónikus myeloid leukémiás, 287 polycythaemia verás, 378 essentialis thrombocythaemiás és 126 myelofibrosisos fordult elő. Célkitűzés: A regisztrált myeloid malignitásokban előfordult szolid tumorok ismertetése. Módszer: A leukémia/lymphoma regiszter társult tumorokra vonatkozó adatainak az elemzése. Eredmények: A 35 éves megfigyelési idő alatt 80 betegben, a myeloid malignitások 4,7%-ában fordult elő társult tumor, 23 akut myeloid leukémiás (3,6%), 18 krónikus myeloid leukémiás (6,6%), 16 polycythaemia verás (5,6%), 18 essentialis thrombocythaemiás (4,8%) és 5 myelofibrosisos (4,0%) betegben. Többes tumorok miatt a tumorok száma 84 volt. Huszonöt betegben a társult tumor a hematológiai malignitás felismerése után jelentkezett, 35-ben azt megelőzően, 20 beteg esetében a kétfajta malignitást egyidejűleg ismerték fel. Következtetések: A társult tumorok gyakorisága megyéjükben kissé elmarad az irodalomban ismertetett arányoktól. Az elemzett epidemiológiai adatok alapján több esetben ok-okozati összefüggés lehetősége merül fel a társulások létrejöttében.

  • 1

    Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and statistical study. Am J Cancer 1932; 16: 1358–1414.

  • 2

    Coleman MP. Multiple primary malignant neoplasms in England and Wales, 1971–1981. Yale J Biol Med. 1986; 59: 517–531.

  • 3

    Tiszlavicz L, Ormos J. Multiple tumors. [Multiplex tumorok.] Orv Hetil. 1988; 129: 281–285. [Hungarian]

  • 4

    Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol. 2009; 471: 85–105.

  • 5

    Liu L, de Vries E, Louwman M, et al. Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer 2011; 128: 1659–1667.

  • 6

    Bánhegyi RJ, Laczó I, Fülöp F, et al. Multiple primary malignancies: common genetics? Case record. [Multiplex daganatos betegség: közös genetika? Esetismertetés.] Hemat Transzf. 2016; 49: 55–58. [Hungarian]

  • 7

    Jakó J, Nagy P, Dauda Gy, et al. Association between haematologic malignancies and cancers. [Malignus haematologiai kórképek és carcinoma társulása.] Orv Hetil. 1994; 135: 2585–2590. [Hungarian]

  • 8

    Jakó J, Szerafin L, Nagy P. Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period). [Szekunder carcinomák malignus hematológiai betegségekben (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983–2002 közötti adatainak elemzése).] Orv Hetil. 2005; 146: 461–469. [Hungarian]

  • 9

    Jakó J, Szerafin L, Nagy P. Second malignant haematologic diseases in patients with carcinoma (analysis of data of leukaemia/lymphoma registry in Szabolcs-Szatmár-Bereg county between 1983–2002). [Carcinomás betegekben kialakuló szekunder malignus hematológiai megbetegedések (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983–2002. évi adatainak elemzése).] Hemat Transzf. 2005; 38: 95–104. [Hungarian]

  • 10

    Szerafin L, Jakó J, Varju L. Occurrence of associated tumours in chronic lymphocytic leukemia. [Társult tumorok előfordulása krónikus lymphoid leukaemiában.] Orv Hetil. 2016; 157: 1752–1756. [Hungarian]

  • 11

    Pál I, Illés Á, Pál T, et al. Multiple myeloma and secondary tumours. [Myeloma mutiplex és szekunder tumorok.] Hemat Transzf. 2017; 50: 39–42. [Hungarian]

  • 12

    Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol. 2005; 16: 228–233.

  • 13

    Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia 2018. Jan 30. [Epub ahead of print].

    • Crossref
    • Export Citation
  • 14

    Curtis RE, Boice JD Jr., Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment of breast cancer. N Engl J Med. 1992; 326: 1745–1751.

  • 15

    Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004; 101: 1529–1536.

  • 16

    Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma. Cancer 2004; 101: 1479–1481.

  • 17

    Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418–429.

  • 18

    Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 2013; 121: 2996–3004.

  • 19

    Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol. 2015; 90: E80-5.

  • 20

    Ghimire KB, Shah BK. Second primary malignancies in adult acute myeloid leukemia – A US population-based study. Anticancer Res. 2014; 34: 3855–3860.

  • 21

    Gale RP, Hlatky L, Sachs RK, et al. Why is there so much therapy-related AML and MDS and so little therapy-related CML? Leuk Res. 2014; 38: 1162–1164.

  • 22

    Iriyama N, Tokuhira M, Takaku T, et al. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leuk Res. 2017; 54: 55–58.

  • 23

    Roy L, Guilhot J, Martineau G, et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myeloid leukemia. Leukemia 2005; 19: 1689–1692.

  • 24

    Pilot PR, Sablinska K, Owen S, et al. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006; 20: 148.

  • 25

    Gunnarsson N, Stenke L, Höglund M, et al. Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era. Brit J Haematol. 2015; 169: 683–688.

  • 26

    Miranda MB, Lauseker M, Kraus M-P, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV. Leukemia 2016; 30: 1255–1262.

  • 27

    Yin X-F, Wang J-H, Li X, et al. Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Clin Lymphoma, Myeloma and Leukemia 2016; 16: 577–581.

  • 28

    Marcheselli L, Polliack A., Tadmor T. Impact of therapy on the development of second malignancies in essential thrombocythemia and polycythemia vera: Are we comfortable about this? Leuk Lymphoma 2016; 57: 6–7.

  • 29

    Ghirardi A, Carobbio A, Masciulli A, et al. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer J. 2018; 8: 5. DOI 10.1038/s41408-017-0038-3.

  • 30

    Hansen IO, Sorensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2017; 98: 75–84.

  • 31

    Masarova L, Cherry M, Newberry KJ, et al. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience. Leuk Lymphoma 2016; 57: 237–239.

  • 32

    Frederiksen H, Körmendiné Farkas D, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011; 118: 6515–6520.

  • 33

    Brunner AM, Hobbs G, Jalbut MM, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma 2016; 57: 1197–1200.

  • 34

    Cherry M, Cardenas-Turanzas M, Pham H, et al. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013; 37: 1472–1476.

  • 35

    Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015; 94: 152–156.

  • 36

    Masarova L, Todisco G, Manshouri T, et al. Therapy-related myelofibrosis does not appear exist. Blood Adv. 2017; 1: 863–866.

  • 37

    Krahling T, Balassa K, Kiss KP, et al. Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100. Cancer Epidemiol Biomartkers Prev. 2016; 25: 98–104.